Founded in 1999,  Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox.  The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development.

    * High-throughput ADME screening
    * Customised ADME assays
    * In silico ADME predictive modeling
    * In vitro toxicology

Life Sciences

Cyprotex

Cyprotex's headquarters in Macclesfield, United Kingdom

Description

People

Jobs